13F Data
13F filer · CIK 1983313

Cutter Capital Management, LP

NEW YORK, NY · filing since Q4 2023 · last filing Jul 24, 2025
Reported value
$0
$-229.6M vs prior
Positions
1
New / sold out
1 / 21
Added / reduced
0 / 0
Turnover
0.0%
buys $0 · sells $229.6M
Top-10 weight
–

Biggest buys vs Q1 2025

ChangeSecurityShares changeChange %Est. trade value
NewN/A0––

Biggest sells vs Q1 2025

ChangeSecurityShares changeChange %Est. trade value
Sold outBRISTOL-MYERS SQUIBB CO-295,000-100.0%$-18.0M
Sold outAMGEN INC-50,000-100.0%$-15.6M
Sold outBIOGEN INC-113,500-100.0%$-15.5M
Sold outLLYELI LILLY & CO-18,000-100.0%$-14.9M
Sold outINSMED INC-186,384-100.0%$-14.2M
Sold outULTRAGENYX PHARMACEUTICAL IN-379,303-100.0%$-13.7M
Sold outBRIDGEBIO PHARMA INC-390,644-100.0%$-13.5M
Sold outPERRIGO CO PLC-479,517-100.0%$-13.4M
Sold outROIVANT SCIENCES LTD-1,300,000-100.0%$-13.1M
Sold outTEVA PHARMACEUTICAL INDS LTD-801,806-100.0%$-12.3M
11 more rows. Subscribe for $29/month to see every row, download the data and use the API.

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q4 2023: $209.2MQ1 2024: $520.9MQ2 2024: $331.3MQ3 2024: $338.8MQ4 2024: $244.0MQ1 2025: $229.6MQ2 2025: $0
Q4 2023Q2 2025

Holdings · Q2 2025

#SecuritySharesValueWeight
1N/AN/A0$0–